The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Objectives In the first-line treatment of non-small cell lung cancer (NSCLC) harboring EGFR
mutations, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has …

The discovery of “driver” genomic alterations in patients with non‐small cell lung cancer
(NSCLC) has dramatically changed the field of thoracic oncology in recent years. The best …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small
cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which …